Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
EV/Core EBITDA

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best Quarterly Growth Mid Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year EV/Core EBITDA History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   EV/Core EBITDA(x) 16.1519.1713.5429.1926.12

What is the latest EV/Core EBITDA ratio of GLAND PHARMA ?

The latest EV/Core EBITDA ratio of GLAND PHARMA is 16.15 based on Mar2025 Consolidated results.
Year EV/Core EBITDA
Mar202516.15
Mar202419.17
Mar202313.54
Mar202229.19
Mar202126.12

How is EV/Core EBITDA of GLAND PHARMA Trending?

Years EV/Core EBITDA % Change
Mar2025 16.15
-15.75
Mar2024 19.17
41.58
Mar2023 13.54
-53.61
Mar2022 29.19
11.75
Mar2021 26.12 -

Other Financial Ratios of GLAND PHARMA


Compare EV/Core EBITDA ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹39,242.8 Cr -3.3% 2.3% 18.4% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹465,711.0 Cr -0.8% 3.5% 14.7% Stock Analytics
DIVIS LABORATORIES ₹192,376.0 Cr -1% 7.3% 7.6% Stock Analytics
TORRENT PHARMACEUTICALS ₹188,655.0 Cr -0.9% 10.1% 44.6% Stock Analytics
CIPLA ₹113,979.0 Cr -2.1% -1.8% -6% Stock Analytics
DR REDDYS LABORATORIES ₹96,204.7 Cr -5.8% -13.2% -7.7% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-3.3%

2.3%

18.4%

SENSEX

-2.7%

-0.2%

-8%


You may also like the below Video Courses